PT888384E - Polipeptido de fusao para influenciar as interaccoes entre proteinas - Google Patents

Polipeptido de fusao para influenciar as interaccoes entre proteinas

Info

Publication number
PT888384E
PT888384E PT97919258T PT97919258T PT888384E PT 888384 E PT888384 E PT 888384E PT 97919258 T PT97919258 T PT 97919258T PT 97919258 T PT97919258 T PT 97919258T PT 888384 E PT888384 E PT 888384E
Authority
PT
Portugal
Prior art keywords
proteins
influence
polypseptide
interaccoes
fusao
Prior art date
Application number
PT97919258T
Other languages
English (en)
Inventor
Stefan J Rose-John
Original Assignee
Stefan Rose John
Walter Rowekamp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stefan Rose John, Walter Rowekamp filed Critical Stefan Rose John
Publication of PT888384E publication Critical patent/PT888384E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5412IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
PT97919258T 1996-03-07 1997-03-07 Polipeptido de fusao para influenciar as interaccoes entre proteinas PT888384E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19608813A DE19608813C2 (de) 1996-03-07 1996-03-07 Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen

Publications (1)

Publication Number Publication Date
PT888384E true PT888384E (pt) 2003-04-30

Family

ID=7787490

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97919258T PT888384E (pt) 1996-03-07 1997-03-07 Polipeptido de fusao para influenciar as interaccoes entre proteinas

Country Status (9)

Country Link
US (1) US7112436B1 (pt)
EP (1) EP0888384B1 (pt)
JP (1) JP4301575B2 (pt)
AT (1) ATE229542T1 (pt)
DE (2) DE19608813C2 (pt)
DK (1) DK0888384T3 (pt)
ES (1) ES2188935T3 (pt)
PT (1) PT888384E (pt)
WO (1) WO1997032891A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
EP2316944A3 (en) * 2000-06-16 2011-11-02 Asterion Limited Binding agents: chimeric ligand/receptor proteins
DE10107737A1 (de) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie
EP1499332A4 (en) * 2002-04-29 2006-12-06 Hadasit Med Res Service COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A VIRAL ONCOLYTIC AGENT
EP1400587A1 (en) * 2002-09-19 2004-03-24 MainGen Biotechnologie GmbH Use of a fusion polypeptide for obtaining pluripotent non-embryonic stem cells
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
DE102004033122A1 (de) * 2004-07-08 2006-02-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vorrichtung und Verfahren zur Analyse von Wechselwirkungen zwischen Biomolekülen
NZ581779A (en) 2005-05-17 2011-09-30 Univ Connecticut Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
EP2335714B1 (en) 2005-06-16 2014-02-26 Hadasit Medical Research Services And Development Ltd. A complex comprising IL-6 and soluble IL-6 receptor for use in the treatment of renal failure
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
US20090098529A1 (en) * 2006-10-16 2009-04-16 Nanhai Chen Methods for attenuating virus strains for diagnostic and therapeutic uses
AU2008269032B2 (en) 2007-06-27 2013-12-05 Novartis Ag Complexes of IL-15 and IL-15Ralpha and uses thereof
WO2009019441A2 (en) * 2007-08-03 2009-02-12 Asterion Limited Granulocyte colony stimulating factor
GB0715213D0 (en) * 2007-08-06 2007-09-12 Asterlon Ltd Igf-1
WO2009069133A2 (en) * 2007-11-28 2009-06-04 Hadasit Medical Research Services And Development Ltd. Methods for the treatment of radiation or chemotherapy-induced tissue damage
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
AU2010205782A1 (en) * 2009-01-16 2011-09-08 Agirx Limited Vaccine compositions
EP2464377B1 (en) 2009-08-14 2016-07-27 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Use of il-15 to increase thymic output and to treat lymphopenia
WO2011151716A1 (en) 2010-06-04 2011-12-08 Lupin Limited Process for the purification of recombinant human il-11
JP6280031B2 (ja) 2012-03-29 2018-02-14 中外製薬株式会社 抗lamp5抗体およびその利用
EP2986312B1 (en) 2013-04-19 2021-12-15 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
EP2992898A1 (en) 2014-09-04 2016-03-09 Klinikum rechts der Isar der Technischen Universität München T-cell adjuvant and its use for therapeutic or prophylactic vaccination
CN110055224B (zh) * 2019-04-03 2023-06-30 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
EP3875111A1 (en) 2020-03-05 2021-09-08 Poznan University Of Medical Sciences Stem cell cancer vaccine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
DK0776339T4 (da) * 1994-07-29 2010-05-25 Sunol Molecular Corp MHC-komplekser og anvendelser deraf

Also Published As

Publication number Publication date
WO1997032891A2 (de) 1997-09-12
DK0888384T3 (da) 2003-03-24
DE59708952D1 (de) 2003-01-23
US7112436B1 (en) 2006-09-26
JP2000506014A (ja) 2000-05-23
JP4301575B2 (ja) 2009-07-22
DE19608813A1 (de) 1997-09-18
EP0888384B1 (de) 2002-12-11
DE19608813C2 (de) 1998-07-02
WO1997032891A3 (de) 1998-02-05
ES2188935T3 (es) 2003-07-01
ATE229542T1 (de) 2002-12-15
EP0888384A2 (de) 1999-01-07

Similar Documents

Publication Publication Date Title
PT888384E (pt) Polipeptido de fusao para influenciar as interaccoes entre proteinas
CY1112101T1 (el) Νευροτροφικοι παραγοντες
TR200000782T2 (tr) Resorsinol türevleri.
ZA9710098B (en) Halogenopyrimidines.
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
WO2000018921A3 (en) Synthetic peptides having fgf receptor affinity
ES2184149T3 (es) Paclitaxeles 6-tio sustituidos.
BR9713727A (pt) Corpos oleosos e proteìnas associados como matrizes de afinicade.
CA2334923A1 (en) Aryl substituted olefinic amines and their use as cholinergic receptors agonists
PT971717E (pt) Amino-acucar citotoxico e derivados de acucar afins de indolopirrolocarbazois
KR960702830A (ko) 방사선 보호제로서의 N-알킬티오 폴리아민 유도체(N-Alkylthio polyaine derivatives as radioprotective agents)
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
DK0506923T3 (da) Et collagenbindende protein samt fremstilling deraf
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
DE69013015D1 (de) Protein aus dem Cytosol, das FK-506 binden kann.
DK0540574T3 (da) Antikoagulationspeptider
ES2115975T3 (es) Derivados de triariletileno utilizados terapeuticamente.
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
PT1011329E (pt) Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
ES2170161T3 (es) Nuevos conjugados de principios activos y proteinas.
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
ZA978233B (en) The use of protein as anti-retroviral agents.
ES1035657Y (es) Brazo lijador neumatico, de articulacion multiple.
ITMC940027A0 (it) Doppia trazione radente sbilanciata verso il centro con molla.